News

The latest from Orpyx

Patent granted for Orpyx technology in New Zealand

Calgary, AB Canada, January 26, 2016 - Orpyx Medical Technologies Inc. announced today that the New Zealand intellectual property office has awarded Orpyx an important patent related to the company’s foundation technology. The “Peripheral Sensory and Supersensory Replacement System” patent covers key inventions used in both Orpyx’s SurroSense Rx (TM) product and future products, such as SurroGait Rx (TM), in New Zealand.

“We are very pleased to see the first of our innovations recognized by the New Zealand intellectual property office,” said Dr. Breanne Everett, CEO of Orpyx Medical Technologies Inc. “Orpyx has made, and continues to make, substantial investment in our intellectual property base, as we lead the world in the development of sensor-based wearable technologies for medical applications.”

SurroSense Rx is designed to actively prevent the complications associated with peripheral neuropathy. The system is comprised of pressure-sensing inserts that wirelessly transmit feedback to the user via a smartwatch or mobile application. The display alerts the user as to when pressure-induced damage is occurring so that behavior can be proactively changed and devastating complications avoided.

About Orpyx Medical Technologies Inc.
Orpyx is a wearable pressure sensor technology company focused on medical applications. To start, Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, peripheral neuropathy, which leads to lack of circulation, numbness, or loss of protective sensation, in the feet. This problem leads to the development of foot sores-or ulcers-which can ultimately lead to amputation and death infection and ulcers in the feet, also known as peripheral neuropathy. This problem affects upwards of 60% of diabetics over the course of their disease and costs the North American health care system over $16.4 billion annually.

For more information, please contact:
Chan Mean
Marketing Manager, Orpyx Medical Technologies Inc.
chan.mean@orpyx.com
+1 403 460 0216 ext. 501

Orpyx LogR™ to be used to investigate markers for cardiovascular disease

Clinical study to begin in 2016

Calgary, AB Canada, January 11, 2016 – Orpyx Medical Technologies Inc. today announced a clinical trial agreement with Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School in Boston, USA. The study will use the Orpyx LogR plantar pressure research system to measure gait and balance parameters in a variety of patients with cardiac and vascular disorders in an attempt to correlate global musculoskeletal changes (as represented by balance/foot pressure physiology) to discrete subsets of cardiovascular disease.

The Orpyx LogR is a solution designed for the accurate, efficient, and real-time measurement of foot and plantar pressure analysis. Comprised of sensor embedded inserts, iOS application and cloud based software for data storage and management, this system is used by researchers to assess foot and ankle health and performance for a variety of different applications including: gait and balance assessments, posture research, rehabilitation, footwear and orthotic design, sport biomechanics, injury prevention, and fall prevention.

“We look forward to testing the role of both gait and balance in the stratification of patients with cardiovascular disease in order to better understand the quality and usability of an integrated foot pressure measurement system as a tool in precision medicine,” said Calum MacRae, MD, PhD, chief, Cardiovascular Medicine at Brigham and Women’s Hospital. “Our goal is to determine if there is a skeletal muscle signature that defines patients with increased perioperative risk or with specific subsets of vascular disease or heart failure.”

“We are very excited about Brigham and Women’s Hospital decision to use the Orpyx LogR in this study. Their reputation and history of innovation provides a unique opportunity to extend the utility of our novel technology and provide continued demonstration of the broader application of our platform in increasingly diverse clinical settings,” said Dr. Breanne Everett, CEO of Orpyx Medical Technologies Inc.

About Orpyx Medical Technologies Inc.
Orpyx is a wearable pressure sensor technology company focused on medical applications. To start, Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, peripheral neuropathy, which leads to lack of circulation, numbness, or loss of protective sensation, in the feet. This problem leads to the development of foot sores-or ulcers-which can ultimately lead to amputation and death infection and ulcers in the feet, also known as peripheral neuropathy. This problem affects upwards of 60% of diabetics over the course of their disease and costs the North American health care system over $16.4 billion annually.

For more information, please contact:
Chan Mean
Marketing Manager, Orpyx Medical Technologies Inc.
chan.mean@orpyx.com
+1 403 460 0216 ext. 501

Orpyx Welcomes New Director

November 15, 2015

News  

David Taylor Brings his Wealth of Experience to the Board

Calgary, AB November 15, 2015 - Orpyx Medical Technologies Inc. announced today that David Taylor has joined its Board of Directors, effective immediately. Mr. Taylor is the President of Resman Holdings Ltd., an investment firm with a diverse portfolio of investments across industries.

“David brings broad and deep business experience from multiple industries that will add a valuable perspective to Orpyx as we grow,” said Dr. Breanne Everett, Founder and CEO. “We are proud to welcome him as a director and I look forward to start working with him.”

In addition to his role at Resman Holdings Ltd., Mr. Taylor’s is concurrently the President of several other businesses, including, Engineered Air, The Glenmore Inn and Convention Center, Airstate Ltd., Thunderstone Quarries Canmore Ltd., and Three Sisters Mountain Village Properties. He also serves on the boards of Sabell Corporation, Stewart Creek Golf Course, Pureleau Industries Inc., Curve Dental, and Edon Management. Mr. Taylor is also active in the community as a member of the Schulich Advisory Council at the University of Calgary School of Engineering, and Chair of BOWDA (Bow Valley Builders and Developers Association).

"I am elated to join the Orpyx Board," said David Taylor. "The team here is delivering life-changing products to patients who really need them and it is a special opportunity to be a part of it."

For more information, please contact:
Chan Mean
Marketing Manager, Orpyx Medical Technologies Inc.
chan.mean@orpyx.com
+1 403 460 0216 ext. 501

The Discovery Channel’s Daily Planet Reviews Orpyx’s LogR System

CALGARY, AB October 27, 2015The LogR from Orpyx Medical Technologies Inc. (“Orpyx”) was featured on The Discovery Channel’s hit television series, Daily Planet. The LogR system is a mobile kit targeted for research-focused plantar pressure measurement – collecting data in real time, in the real world. Samuel Blades, PhD candidate from the University of Victoria’s Department of Exercise was approached by the television station to record a segment on his applied sports science research. As described in the segment, the progress made to date is nothing short of “revolutionary”.

Alongside Canadian top athlete Hillary Stellingwerff, Blades discussed the importance of runners to assess how the foot is interacting with the ground underneath them, analyze the patterns and unveil areas of the foot that may pose a certain risk. Most athletes do not run on the fancy treadmills that can be found in a lab setting; they are outdoors, which is where Orpyx’s LogR system provides a superior measurement system.

The LogR is a tool to accurately and efficiently measure foot pressures for analysis. Comprised of sensor embedded inserts, real-time iOs application and cloud based software for data storage and management, this system is crucial to assess overall foot and ankle health for a myriad of different applications including: gait and balance assessments, posture research, rehabilitation, footwear and orthotic, design, sport biomechanics, injury prevention, fall prevention and more.

The work done to date would not be possible without the partnership of Mitacs, Own the Podium, the University of Victoria, Canadian Sport Institute Pacific and Orpyx to provide a new opportunity for applied sport science research.  To watch the segment, click here

On November 12, 2013 the Ward of the 21st Century ("W21C") hosted its first Innovation Academy.  In partnership with an international network, this event focused on identifying and nurturing health innovations that will contribute to the improvement of health service safety and quality of care both now and in the future.

W21C followed up with Orpyx to get an update on their progress over the past year.  Watch the update here.

Orpyx Gives Online Visitors A Warmer Welcome

CALGARY, AB August 13, 2015 – Orpyx Medical Technologies Inc. (“Orpyx”) is pleased to announce the launch of its fully revamped website: www.orpyx.com. The website has been redesigned with our customer needs in mind. We’ve focused on making the site easier to navigate, more impactful and providing greater support resources.

A big part of our mission is to make wearable health technologies available and accessible to the people who need them the most – the patients. The Orpyx website assists patients with peripheral neuropathy, their families and their providers in making well-informed decisions regarding their care plans. The website features Orpyx’s flagship product, the SurroSense Rx™ system, which is a tool to help actively prevent the complications relating to peripheral neuropathy, aid in the healing of existing complications and track progress.

Of course, the launch of our redesigned website is just the beginning. We will be continuing to improve the content, features and resources in the near and distant future.

ABOUT ORPYX MEDICAL TECHNOLOGIES:

Orpyx is a wearable pressure sensor technology company focused on medical applications. To start, Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, lack of circulation, numbness, infection and ulcers in the feet, also known as peripheral neuropathy. This problem affects upwards of 60% of diabetics over the course of their disease and costs the health care system over $14 billion annually.

 The SurroSense Rx system is a tool to help actively prevent the complications associated with peripheral neuropathy, aid in the healing of existing complications and track progress. The system is comprised of pressure-sensing inserts that wirelessly transmit feedback to the user via smartwatch or mobile application. The display alerts the user as to when pressure-induced damage is occurring so that behaviour can be proactively changed and devastating complications avoided.

 In addition to the benefits of having real-time feedback, the system also tracks compliance and performance metrics over time so that the patient and primary care team can monitor progress and adjust care recommendations accordingly.

Orpyx was recently mentioned in the July 2015 edition of the Lower Extremity Review.  At the International Working Group on the Diabetic Foot in the Netherlands, pressure offloading was a hot topic.  Lower Extremity Review author, Cary Groner, provides a synopsis of the conference and what clinicians are suggestion for best practice recommendations on offloading.  They also discuss Orpyx's smart insoles!  Read the full article here.

Guest blog post by: Expert Tech Blogger - The Clover Heart

Technological advancements have ushered in a new dawn of health and fitness, where tracking our well-being can be done via our smartphones and tablets. Today, we have thousands of health applications for Android and iOS devices that allow us to immediately count the calories we have burnt and the distance we have ran, walked or cycled. In a 2014 report entitled, mHealth App Developer Economics, it revealed that the worldwide revenue for mobile health app reached $2.4 billion in 2013, and they expect that it will grow to $26 billion by the end of 2017 But, apart from mobile applications, there are other health-related technologies that are also garner a lot of press within the tech domain. We have listed some of the buzz tech devices that you should seriously consider purchasing in the coming months.

Wearable devices

The demand for wearable devices is expected to skyrocket in the coming years, with the United States and Australia leading the way in commercial sales. Research firm Telsyte revealed in a report that the smartwatch market in Australia will exceed $400 million by 2018, replacing nearly 17 million smartphones as the go-to device for many consumers. The demand for wearable devices strengthens as it promises to provide accurate, fast, and real-time health data to its users, through its sensors that track heart rate, stress levels, sleeping patterns and a whole host of other variables that aim to improve one’s overall wellbeing. The latest wearables are said to have focused on assisting patients with specialized medical needs. A good example of this is the SurroSense Rx™ system, which is a three-piece wearable device that helps avoid the devastating complications as a result of diabetic peripheral neuropathy, including blisters, infection, ulceration and ultimately amputation. The other wearable devices currently on the market are more focused on providing heart rate, rate of activity, and distance data to its users opposed to the specific, meaningful health data that the SurroSense Rx™ offers.

Smartphones with built-in health apps

Prior to wearable devices, mobile apps assisted people in tracking their health vitals. Today, mobile companies such as Samsung and Apple have released their latest flagship handsets with built-in health tracking apps that provide real-time data to its users. In particular, the new Galaxy S6 Edge features a “re-imagined” version of their propriety health application, the S Health that provides more accurate and real-time tracking of the health.

Smart scales

The smart and wireless trend is really taking off. Old bathroom scales tend to get replaced with digital, smarter, or Wi-Fi capable weighing scales that can calculate not only your weight, but also your body mass index (BMI) and body fat percentage. Known for releasing wearable devices, Fitbit has expanded their range of products to give way for their Aria Wi-Fi Smart Scale that can monitor the weight of up to seven different users. All the data gathered by the smart scale is uploaded directly online to the Fitbit account of the user or it can also be accessed in real-time via the Fitbit’s iPhone app. In Engadget's review of the product, they gave it a 90/100 score, with the following concluding statement: "We like it!" It’s inevitable that there will be more revolutionary health tracking items, as consumers become proactive in monitoring their fitness and wellbeing. What other revolutionary health technologies do you expect to see released soon? Or even better, what do you feel we need to see to help us maintain our health better?

Orpyx® Receives Award for "Coolest Technology"

Calgary, AB April 21, 2015 - Orpyx Medical Technologies Inc. (“Orpyx”) participated in the pitch competition at the 48 Hours in the Hub event, an annual intensive two-day program in Cambridge/Boston. Orpyx’s President, Lew Turnquist, competed against other Canadian companies in the Life Sciences/ Health IT stream and was awarded the prize for “Coolest Technology”. The award was delivered by Gaurav Jain, who was recently named one of Forbes’ 30 under 30 in Venture Capital 2015.

The Consulate General of Canada in Boston and the Canadian Entrepreneurs in New England (CENE) selected 24 innovative Canadian companies to participate in the 48 Hours in the Hub event. It is an opportunity for Canadian companies to gain visibility in the local Boston business and investment community.

ABOUT CENE:

The CENE (Canadian Entrepreneurs in New England) is a non-profit, member-driven organization dedicated to supporting Canadian technology and life science entrepreneurship. It is comprised of a select group of Canadians based primarily in the U.S., including executives of leading technology and life-sciences companies, experienced start-up entrepreneurs and venture capital investors. 


ABOUT ORPYX MEDICAL TECHNOLOGIES:

Orpyx is a wearable pressure sensor technology company focused on medical applications. To start, Orpyx’s primary intention is to address the world’s growing epidemic of diabetes and its associated complications, most notably, lack of circulation, numbness, infection and ulcers in the feet, also known as peripheral neuropathy. This problem affects upwards of 60% of diabetics over the course of their disease and costs the health care system over $14 billion annually.

The SurroSense Rx system is a tool to help actively prevent the complications associated with peripheral neuropathy and track progress. The system is comprised of pressure-sensing inserts that wirelessly transmit feedback to the user via smartwatch or mobile application. The display alerts the user as to when pressure-induced damage is occurring so that behaviour can be proactively changed and devastating complications avoided.

In addition to the benefits of having real-time feedback, the system also tracks compliance and performance metrics over time so that the patient and primary care team and monitor progress and adjust care recommendations accordingly.

For more information, please contact:

Stephanie Zakala
Marketing & Inside Sales Manager, Orpyx Medical Technologies Inc.
stephanie.zakala@orpyx.com
403-460-0216

It’s no secret that diabetes is a difficult disease to manage with many co-morbid conditions associated with it. One of the most common complications related to the disease is peripheral neuropathy. Patients with diabetes can lose sensation in their feet, which can lead to ulcers, infection and in many cases amputation.

We often hear that the best way to protect your feet is to get off them. If you are living in a bubble then yes, this may work just fine. But for the majority of people, being sedentary is not an option.

On the other hand, increasing activity levels is programmed in many doctor/patient visits to encourage healthy, active lifestyles.

These varying recommendations can be very confusing – how can we manage dosage of activity while protecting the feet?

Imagine now…the best of both worlds! Managing activity while protecting the feet.

Trends from consumer electronics tend to carry over into healthcare. If you look at wearable technologies over the past decade, there has been exponential growth. It’s apparent that people are starting to get and desire wearable technologies that monitor themselves and their biometric data. Moving from consumer activity tracking and athletics products to a medical device/products makes a lot of sense.

So what does this mean for patients with diabetic peripheral neuropathy?

There are implications here that can significantly impact foot health. Integrating practical sensory substitution technologies that monitor activities related to foot health and notify the user of harm during daily living can and will impact the way we manage foot health today.

In fact, interim data with the SurroSense Rx system, a mobile health-offloading device, suggests that users score the device high on satisfaction and perceived benefit ratings. Most notably, we see about a 95% adherence rate with this device suggesting that patients are devoted to personalized offloading.

It’s clear that technology has become ubiquitous in our activities of daily living – it’s now time that we empower people to manage activity while protecting their feet.

1 2 3 Next »